Your AI-Trained Oncology Knowledge Connection!
The approval of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer is generating hopes that similar strategies also may be effective against HER2-expressing gastric and colorectal cancers, according to a panel of experts in gastrointestinal malignancies.
Sara A. Hurvitz, MD, Neelima Denduluri, MD, and Madelaine Kuiper, MSN, RN, discuss the rise of HER2-targeted therapies and their implications on the field.
Diego Villa, MD, MPH, discusses the benefit of bendamustine and rituximab versus R-CHOP in transplant-eligible and -ineligible patients with mantle cell lymphoma.
The FDA has granted a priority review designation to a supplemental new drug application for selinexor as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma, not otherwise specified, who have received ≥2 prior therapies.
James J. Harding, MD, discusses the evolving treatment landscape in frontline hepatocellular carcinoma and ongoing trials that may revolutionize the space.
Neelima Denduluri, MD, sheds light on the use of genomic assays in early-stage HR-positive/HER2-negative breast cancer, as well as the agents that are prolonging survival in patients with metastatic HER2-positive disease.
The FDA has issued a complete response letter to 6 supplemental biologics license applications that would have updated the dosing schedule for pembrolizumab to include an every-6-weeks option at 400 mg over 30-minute infusions across multiple indications.
The FDA has granted a breakthrough therapy designation to the combination of enfortumab vedotin-ejfv and pembrolizumab as a first-line treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy.
Karen Reckamp, MD, MS, highlights the different agents that have been developed to target rarer abnormalities in non–small cell lung cancer.
The FDA has granted a priority review designation to a supplemental biologics license application for single-agent atezolizumab as a frontline treatment for patients with advanced nonsquamous or squamous non–small cell lung cancer without EGFR or ALK mutations who have high PD-L1 expression on tumor cells or tumor-infiltrating immune cells, defined as TC3/IC3 wild-type.
Ruth O’Regan, MD, shares her perspective on the use of biosimilars in breast cancer and their future in oncology.
William L. Dahut, MD, discusses the natural history trial, the implications of the PROfound study, and the importance of screening for men at a high risk for developing prostate cancer.
Anne Chiang, MD, PhD, discusses the currently available treatments and ongoing research in ALK-positive non–small cell lung cancer.
Karyn Aalami Goodman, MD, MS, an internationally recognized expert on gastrointestinal cancers, has joined the Icahn School of Medicine at Mount Sinai as Associate Director for Clinical Research at The Tisch Cancer Institute. She is also Professor and Vice Chair for Research and Quality in the Department of Radiation Oncology.
The combination of nivolumab and the investigational CSF-1R inhibitor cabiralizumab with and without chemotherapy did not improve progression-free survival compared with chemotherapy alone in patients with advanced pancreatic cancer, missing the primary endpoint of a phase II trial (NCT03336216).
Jean Lopategui, MD, reflects on the use of molecular testing for patients with non–small cell lung cancer.
Hernan Vargas, MD, FACS, discusses the criteria that are used to determine the appropriate surgical intervention for patients with node-positive breast cancer and shared questions that still need to be addressed in the space.
Adjuvant treatment with ipilimumab, when given at a 3-mg/kg dose, was found to improve overall survival compared with high-dose interferon alfa in patients with high-risk melanoma.
Thomas J. Lynch Jr, MD, discusses his journey in the field of oncology, his transition to Fred Hutchinson Cancer Research Center, and his goals for the institution going forward.
Julia Fehniger, MD, discusses emerging strategies in the treatment paradigm for patients with BRCA1/2-mutant endometrial cancer.
Alexey V. Danilov, MD, PhD, discusses the ELEVATE-TN trial and other potentially practice-changing BTK inhibitor combinations expected to emerge in chronic lymphocytic leukemia.
Ghassan K. Abou-Alfa, MD, discusses the treatment options that have emerged in advanced hepatocellular carcinoma and the work being done to determine optimal sequencing strategies.
Investigators are exploring concurrent PARP inhibition and definitive regional radiotherapy in patients with metastatic invasive cervical cancer in an ongoing phase I/II study.
Jean Wright, MD, discusses the evolution of radiation oncology in early-stage breast cancer and how novel radiation modalities are poised to transform the field.
Girish Putcha, MD, PhD, provides insight on the study results and highlights the advantages of using a multiomic, blood-based assay in colorectal cancer screening.
The FDA has granted a priority review designation to a new drug application for lurbinectedin as a treatment for patients with small cell lung cancer who have progressed following platinum-containing therapy.
David H. Ilson, MD, PhD, discusses the treatment landscape of advanced gastric cancer and the research being done to define a role for novel agents in this space.
Andrea Cercek, MD, shares insight on treatment selection, the importance of molecular testing, and unanswered questions with tumor sidedness in patients with newly diagnosed metastatic colorectal cancer.
Jasmeet C. Singh, MD, discusses the findings of a retrospective analysis and how they may impact treatment for patients with HER2-positive breast cancer.